At present, China's in vitro diagnostic industry (IVD) is gradually emerging. Compared with the mature foreign market, the domestic IVD market has a small base, but it is expected to maintain good and rapid growth thanks to the development trend of medical reform and precision medical treatment . Founded in 2003, Ningbo Meikang Biotechnology Co., Ltd. is a national key high-tech enterprise specializing in the research, development, production, sales and service of biotechnology products. It is an A-share listed company. The main industries of Meikang Bio are in vitro biochemical diagnostic reagents, instruments and independent third-party medical diagnostic services. Recently, the reporter conducted an exclusive interview with Mr. Zou Bingde, Chairman of Meikang Biotechnology Co., Ltd. on the development status of the domestic IVD market and the development trend of the market. Interview summary Question 1: In what aspects has the development of the IVD industry been reflected in recent years? Zou Bingde: First, from the perspective of industry structure, the situation of M&D in the IVD industry has become more and more fierce. The integration and reorganization of enterprises by means of mergers and acquisitions has become the only way for the development of the industry. At the same time, the product line layout has expanded from the low-end biochemical diagnostic field to the high-end immunodiagnosis and molecular diagnostics, and a number of new leading IVD companies have emerged in different segments. Second, in the context of big data and new medical reform, the "Internet + IVD" model was born, IVD companies have begun to build medical inspection information platform, and portable rapid detection equipment (POCT) and mobile cloud platform, personal user intelligent terminal and The hospital information system is connected to achieve the interconnection of test results between regional medical associations, improve the service level of primary medical institutions, and promote the implementation of the graded diagnosis and treatment system. (And the Meikang Biological Cloud Health System is taken as an example for detailed explanation.) Third, with the continuous improvement of domestic talent reserve capacity and biotechnology level, product update speed is accelerated, and research and development time is also greatly shortened. In particular, the emergence of early detection programs for diseases will play an important role in the early diagnosis and prevention of diseases, and even change the existing medical habits. Canned Bigeye Tuna,Bigeye Tuna Chunk in Oil Can,Tuna Salad Can Zhejiang ocean family co.,ltd , https://www.ocean-family.com
Zou Bingde, Chairman of Meikang Bio, will establish IVD eco-industrial chain